請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/44099完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 于明暉(Ming-Whei Yu) | |
| dc.contributor.author | Wei-Chih Liao | en |
| dc.contributor.author | 廖偉智 | zh_TW |
| dc.date.accessioned | 2021-06-15T02:39:53Z | - |
| dc.date.available | 2012-09-16 | |
| dc.date.copyright | 2009-09-16 | |
| dc.date.issued | 2009 | |
| dc.date.submitted | 2009-08-12 | |
| dc.identifier.citation | 1. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2008. CA Cancer J Clin 58:71-96, 2008.
2. Li D, Xie K, Wolff R, et al: Pancreatic cancer. Lancet 363:1049-57, 2004. 3. Sperti C, Pasquali C, Piccoli A, et al: Recurrence after resection for ductal adenocarcinoma of the pancreas. World J Surg 21:195-200, 1997. 4. Sohn TA, Yeo CJ, Cameron JL, et al: Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 4:567-79, 2000. 5. Sener SF, Fremgen A, Menck HR, et al: Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database. J Am Coll Surg 189:1-7, 1999. 6. Luster AD: Chemokines--chemotactic cytokines that mediate inflammation. N Engl J Med 338:436-45, 1998. 7. Struyf S, Proost P, Van Damme J: Regulation of the immune response by the interaction of chemokines and proteases. Adv Immunol 81:1-44, 2003. 8. Andre F, Cabioglu N, Assi H, et al: Expression of chemokine receptors predicts the site of metastatic relapse in patients with axillary node positive primary breast cancer. Ann Oncol 17:945-51, 2006. 9. Muller A, Homey B, Soto H, et al: Involvement of chemokine receptors in breast cancer metastasis. Nature 410:50-6, 2001. 10. Zlotnik A: Chemokines in neoplastic progression. Semin Cancer Biol 14:181-5, 2004. 11. Saur D, Seidler B, Schneider G, et al: CXCR4 expression increases liver and lung metastasis in a mouse model of pancreatic cancer. Gastroenterology 129:1237-50, 2005. 12. Kim J, Mori T, Chen SL, et al: Chemokine receptor CXCR4 expression in patients with melanoma and colorectal cancer liver metastases and the association with disease outcome. Ann Surg 244:113-20, 2006. 13. Kim J, Takeuchi H, Lam ST, et al: Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival. J Clin Oncol 23:2744-53, 2005. 14. Phillips RJ, Burdick MD, Lutz M, et al: The stromal derived factor-1/CXCL12-CXC chemokine receptor 4 biological axis in non-small cell lung cancer metastases. Am J Respir Crit Care Med 167:1676-86, 2003. 15. Thomas RM, Kim J, Revelo-Penafiel MP, et al: The chemokine receptor CXCR4 is expressed in pancreatic intraepithelial neoplasia. Gut 57:1555-60, 2008. 16. Koshiba T, Hosotani R, Miyamoto Y, et al: Expression of stromal cell-derived factor 1 and CXCR4 ligand receptor system in pancreatic cancer: a possible role for tumor progression. Clin Cancer Res 6:3530-5, 2000. 17. Marchesi F, Monti P, Leone BE, et al: Increased survival, proliferation, and migration in metastatic human pancreatic tumor cells expressing functional CXCR4. Cancer Res 64:8420-7, 2004. 18. Hermann PC, Huber SL, Herrler T, et al: Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 1:313-23, 2007. 19. Mori T, Doi R, Koizumi M, et al: CXCR4 antagonist inhibits stromal cell-derived factor 1-induced migration and invasion of human pancreatic cancer. Mol Cancer Ther 3:29-37, 2004. 20. Wehler T, Wolfert F, Schimanski CC, et al: Strong expression of chemokine receptor CXCR4 by pancreatic cancer correlates with advanced disease. Oncol Rep 16:1159-64, 2006. 21. Greene FL, Page DL, Fleming ID, Fritz AG, Balch CM, Haller DG, Morrow M: Exocrine pancreas, in Greene FL, Page DL, Fleming ID, Fritz AG, Balch CM, Haller DG, Morrow M (ed): AJCC Cancer Staging Manual (ed 6). New York, NY, Springer-Verlag, 2002, pp 157-64. 22. Klein JP, Moeschberger ML: Semiparametric proportional hazards regression with fixed covariates, in Klein JP, Moeschberger ML (eds): Survival analysis: techniques for censored and truncated data (ed 2). New York, Springer, 2003, pp 276-282. 23. Klein JP, Moeschberger ML: Inference for parametric regression models, in Klein JP, Moeschberger ML (eds): Survival analysis: techniques for censored and truncated data (ed 2). New York, Springer, 2003, pp 393-409. 24. Allison PD: Estimating parametric models with PROC LIFEREG, in Allison P (ed): Survival anlysis using the SAS system: a pratical guide. Cary, NC, SAS Institute Inc., 1995, pp 61-109. 25. McShane LM, Altman DG, Sauerbrei W, et al: Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 23:9067-72, 2005. 26. von Elm E, Altman DG, Egger M, et al: Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ 335:806-8, 2007. 27. Lim JE, Chien MW, Earle CC: Prognostic factors following curative resection for pancreatic adenocarcinoma: a population-based, linked database analysis of 396 patients. Ann Surg 237:74-85, 2003. 28. Hess KR, Varadhachary GR, Taylor SH, et al: Metastatic patterns in adenocarcinoma. Cancer 106:1624-33, 2006. 29. Kim J, Reber HA, Dry SM, et al: Unfavourable prognosis associated with K-ras gene mutation in pancreatic cancer surgical margins. Gut 55:1598-605, 2006. 30. Kimsey TF, Campbell AS, Albo D, et al: Co-localization of macrophage inflammatory protein-3alpha (Mip-3alpha) and its receptor, CCR6, promotes pancreatic cancer cell invasion. Cancer J 10:374-80, 2004. 31. Ghadjar P, Coupland SE, Na IK, et al: Chemokine receptor CCR6 expression level and liver metastases in colorectal cancer. J Clin Oncol 24:1910-6, 2006. 32. Sayehmiri K, Eshraghian MR, Mohammad K, et al: Prognostic factors of survival time after hematopoietic stem cell transplant in acute lymphoblastic leukemia patients: Cox proportional hazard versus accelerated failure time models. J Exp Clin Cancer Res 27:74, 2008. 33. Kleinbaum DG, Klein M: Parametric survival models, in Kleinbaum DG, Klein M (eds): Survival Analysis: A Self-Learning Text (ed 2). New York, NY, Springer Verlag, 2005, pp 258-330. 34. Rothman KJ, Greenland S: Precision and validity of studies, in Rothman KJ, Greenland S (eds): Modern Epidemiology (ed 2). Philadelphia, PA, Lippincott-Raven Publishers, 1998, pp 115-134. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/44099 | - |
| dc.description.abstract | 背景：胰臟癌病患接受腫瘤切除手術後有60％會發生肝臟復發，其預後極差。實驗性研究顯示趨化素受器CXCR4為胰臟癌病患手術後肝臟轉移之重要因子，然而其與病患預後之關連未曾獲得證實。本研究目的在探討CXCR4之表現與胰臟癌術後無肝臟復發存活及總存活之關連。
方法：共有97位接受腫瘤切除手術之患者被納入研究。利用免疫組織染色測定CXCR4之表現，然後以Kaplan-Meier estimate及多變數proportional hazards 模型分析CXCR4表現與無肝臟復發存活及總存活之關係。 結果：腫瘤CXCR4陽性之病患其預後較CXCR4陰性者為差，其無肝臟復發存活 （中位數8.7 vs 39.7個月，p＝0.004）及總存活（中位數10.2 vs 22.3個月，p<0.001）較短。CXCR4陽性之IIa期病患其總存活與IIb期者相近，較CXCR4陰性之IIa期患者顯著較短（p＝0.002）。CXCR4陽性對於肝臟復發與因胰臟癌死亡之校正危險比分別為2.22（p＝0.018）及1.78（p＝0.041）。 結論：胰臟癌表現CXCR4為術後肝臟復發與死亡之獨立預後因子。CXCR4免疫組織染色可以提供其他已知之預後預測因子所無法提供之資訊，且可改善TNM分期對術後存活之預測。 | zh_TW |
| dc.description.abstract | ABSTRACT
Purpose: Liver recurrence develops in 60% of patients who undergo resection for pancreatic cancer (PC) and predicts a dismal prognosis. Experimental evidences suggested chemokine receptor CXCR4 as the key mediator of liver metastasis in PC, but its significance has not been investigated with patient outcome. This study aimed to investigate the potential associations between CXCR4 expression and liver recurrence or overall survival after resection for PC. Methods: Ninety-seven patients undergoing R0 resection were evaluated. CXCR4 expression was analyzed by immunohistochemistry, and its association with liver recurrence-free or overall survival was analyzed by Kaplan-Meier estimates and multivariable proportional hazards models. Results: Patients with CXCR4-positive tumors had worse prognosis than those with CXCR4-negative tumors, with a shorter liver recurrence-free survival (median: 8.7 vs. 39.7 months; p=0.004) and overall survival (median: 10.2 vs. 22.3 months; p<0.001). Overall survival for CXCR4-positive stage IIa patients was similar to stage IIb patients and significantly shorter than CXCR4-negative stage IIa patients (p=0.002). The adjusted hazard ratio of positive CXCR4 immunostaining was 2.22 for liver recurrence (p=0.018), and 1.78 for death due to PC (p=0.041), respectively. Conclusion: CXCR4 expression is an independent predictor of early liver recurrence and death after resection for PC. CXCR4 immunohistochemistry provides exclusive prognostic information that can not be replaced by known prognostic factors and supplements TNM stage in predicting survival. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-15T02:39:53Z (GMT). No. of bitstreams: 1 ntu-98-R95842013-1.pdf: 408697 bytes, checksum: d02aa1c824b9e876bcd9c0d6ea488cca (MD5) Previous issue date: 2009 | en |
| dc.description.tableofcontents | 1.中文摘要 4
2. Abstract 5 3. Introduction 7 4. Materials and methods 8 5. Results 12 6. Discussion 16 7. Reference 21 8. Appendix 26 | |
| dc.language.iso | en | |
| dc.subject | 總存活 | zh_TW |
| dc.subject | CXCR4 | zh_TW |
| dc.subject | 胰臟癌 | zh_TW |
| dc.subject | 肝臟復發 | zh_TW |
| dc.subject | survival | en |
| dc.subject | liver recurrence | en |
| dc.subject | pancreatic cancer | en |
| dc.subject | CXCR4 | en |
| dc.title | 腫瘤CXCR4表現與胰臟癌術後存活之關係:回溯性世代研究 | zh_TW |
| dc.title | Tumor Expression of CXCR4 and Survival after Resection for Pancreatic Cancer: a Retrospective Cohort Study | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 97-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.coadvisor | 林肇堂(Jaw-Town Lin) | |
| dc.contributor.oralexamcommittee | 吳明賢(Ming-Shiang Wu) | |
| dc.subject.keyword | CXCR4,胰臟癌,肝臟復發,總存活, | zh_TW |
| dc.subject.keyword | CXCR4,pancreatic cancer,liver recurrence,survival, | en |
| dc.relation.page | 36 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2009-08-12 | |
| dc.contributor.author-college | 公共衛生學院 | zh_TW |
| dc.contributor.author-dept | 流行病學研究所 | zh_TW |
| 顯示於系所單位： | 流行病學與預防醫學研究所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-98-1.pdf 未授權公開取用 | 399.12 kB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。